Safety and Efficacy of Concurrent Atezolizumab/Bevacizumab or Nivolumab Combination Therapy with Yttrium-90 Radioembolization of Advanced Unresectable Hepatocellular Carcinoma.

To evaluate the safety and efficacy of combining yttrium-90 radioembolization (Y90-RE) with immune checkpoint inhibitor therapy, consecutive advanced unresectable hepatocellular carcinoma (HCC) patients treated between 2016 and 2022 with atezolizumab/bevacizumab or nivolumab within three-months pre-...

Descripción completa

Detalles Bibliográficos

Publicado en:	Current Oncology Vol. 30; no. 12; pp. 10100 - 10111
Autores principales:	Villalobos, Alexander, Dabbous, Howard Hussein, Little, Olivia, Gbolahan, Olumide Babajide, Akce, Mehmet, Lilly, Meghan Allegra, Bercu, Zachary, Kokabi, Nima
Formato:	Journal Article
Publicado:	MDPI Dec2023
Acceso en línea:	Ver este registro en EBSCOhost